{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:14:42Z","timestamp":1791893682151,"version":"4.3.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2012,7,6]],"date-time":"2012-07-06T00:00:00Z","timestamp":1341532800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1007\/s12185-012-1132-8","type":"journal-article","created":{"date-parts":[[2012,7,14]],"date-time":"2012-07-14T09:25:05Z","timestamp":1342257905000},"page":"308-319","source":"Crossref","is-referenced-by-count":25,"title":["Rapid and sustained increase of large granular lymphocytes and rare cytomegalovirus reactivation during dasatinib treatment in chronic myelogenous leukemia patients"],"prefix":"10.1007","volume":"96","author":[{"given":"Hideo","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shizuka","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miyuki","family":"Usuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,7,6]]},"reference":[{"key":"1132_CR1","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1158\/1078-0432.CCR-07-4393","volume":"14","author":"R Weichsel","year":"2008","unstructured":"Weichsel R, Dix C, Wooldridge L, Clement M, Fenton-May A, Sewell AK, et al. Profound inhibition of antigen-specific T-cell effector functions by dasatinib. Clin Cancer Res. 2008;14:2484\u201391.","journal-title":"Clin Cancer Res"},{"key":"1132_CR2","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1182\/blood-2007-04-084814","volume":"111","author":"AE Schade","year":"2008","unstructured":"Schade AE, Schieven GL, Townsend R, Jankowska AM, Susulic V, Zhang R, et al. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood. 2008;111:1366\u201377.","journal-title":"Blood"},{"key":"1132_CR3","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.exphem.2008.09.013","volume":"37","author":"CK Fraser","year":"2009","unstructured":"Fraser CK, Blake SJ, Diener KR, Lyons AB, Brown MP, Hughes TP, et al. Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo. Exp Hematol. 2009;37:256\u201365.","journal-title":"Exp Hematol"},{"key":"1132_CR4","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1182\/blood-2004-07-2527","volume":"105","author":"R Seggewiss","year":"2005","unstructured":"Seggewiss R, Lore K, Greiner E, Magnusson MK, Price DA, Douek DC, et al. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood. 2005;105:2473\u20139.","journal-title":"Blood"},{"key":"1132_CR5","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1111\/j.1582-4934.2008.00234.x","volume":"12","author":"J Chen","year":"2008","unstructured":"Chen J, Schmitt A, Chen B, Rojewski M, Rubeler V, Fei F, et al. Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signalling. J Cell Mol Med. 2008;12:2107\u201318.","journal-title":"J Cell Mol Med"},{"key":"1132_CR6","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","volume":"362","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362:2260\u201370.","journal-title":"N Engl J Med"},{"key":"1132_CR7","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/j.1365-2362.2009.02206.x","volume":"39","author":"C Sillaber","year":"2009","unstructured":"Sillaber C, Herrmann H, Bennett K, Rix U, Baumgartner C, Bohm A, et al. Immunosuppression and atypical infections in CML patients treated with dasatinib at 140\u00a0mg daily. Eur J Clin Invest. 2009;39:1098\u2013109.","journal-title":"Eur J Clin Invest"},{"key":"1132_CR8","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/leu.2009.46","volume":"23","author":"S Mustjoki","year":"2009","unstructured":"Mustjoki S, Ekblom M, Arstila TP, Dybedal I, Epling-Burnette PK, Guilhot F, et al. Clonal expansion of T\/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia. 2009;23:1398\u2013405.","journal-title":"Leukemia"},{"key":"1132_CR9","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3324\/haematol.13151","volume":"94","author":"DH Kim","year":"2009","unstructured":"Kim DH, Kamel-Reid S, Chang H, Sutherland R, Jung CW, Kim HJ, et al. Natural killer or natural killer\/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia. Haematologica. 2009;94:135\u20139.","journal-title":"Haematologica"},{"key":"1132_CR10","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s12185-010-0565-1","volume":"91","author":"Y Nagata","year":"2010","unstructured":"Nagata Y, Ohashi K, Fukuda S, Kamata N, Akiyama H, Sakamaki H. Clinical features of dasatinib-induced large granular lymphocytosis and pleural effusion. Int J Hematol. 2010;91:799\u2013807.","journal-title":"Int J Hematol"},{"key":"1132_CR11","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.leukres.2010.08.022","volume":"35","author":"JN Valent","year":"2011","unstructured":"Valent JN, Schiffer CA. Prevalence of large granular lymphocytosis in patients with chronic myelogenous leukemia (CML) treated with dasatinib. Leuk Res. 2011;35:e1\u20133.","journal-title":"Leuk Res"},{"key":"1132_CR12","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1038\/leu.2011.135","volume":"25","author":"A Kreutzman","year":"2011","unstructured":"Kreutzman A, Ladell K, Koechel C, Gostick E, Ekblom M, Stenke L, et al. Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation. Leukemia. 2011;25:1587\u201397.","journal-title":"Leukemia"},{"key":"1132_CR13","doi-asserted-by":"crossref","first-page":"668","DOI":"10.3109\/10428194.2010.550074","volume":"52","author":"JJ Powers","year":"2011","unstructured":"Powers JJ, Dubovsky JA, Epling-Burnette PK, Moscinski L, Zhang L, Mustjoki S, et al. A molecular and functional analysis of large granular lymphocyte expansions in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors. Leuk Lymphoma. 2011;52:668\u201379.","journal-title":"Leuk Lymphoma"},{"key":"1132_CR14","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1182\/blood-2009-12-256800","volume":"116","author":"A Kreutzman","year":"2010","unstructured":"Kreutzman A, Juvonen V, Kairisto V, Ekblom M, Stenke L, Seggewiss R, et al. Mono\/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. Blood. 2010;116:772\u201382.","journal-title":"Blood"},{"key":"1132_CR15","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1182\/blood-2010-05-283127","volume":"116","author":"F Ravandi","year":"2010","unstructured":"Ravandi F. Dasatinib, an immunomodulator? Blood. 2010;116:673\u20134.","journal-title":"Blood"},{"key":"1132_CR16","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/cncr.24734","volume":"116","author":"K Porkka","year":"2010","unstructured":"Porkka K, Khoury HJ, Paquette RL, Matloub Y, Sinha R, Cortes JE. Dasatinib 100\u00a0mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. Cancer. 2010;116:377\u201386.","journal-title":"Cancer"},{"key":"1132_CR17","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","volume":"110","author":"HM Kantarjian","year":"2007","unstructured":"Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007;110:3540\u20136.","journal-title":"Blood"},{"key":"1132_CR18","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/leu.2010.215","volume":"25","author":"E Jabbour","year":"2011","unstructured":"Jabbour E, Deininger M, Hochhaus A. Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia. 2011;25:201\u201310.","journal-title":"Leukemia"},{"key":"1132_CR19","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1038\/sj.leu.2403202","volume":"17","author":"JJ Dongen van","year":"2003","unstructured":"van Dongen JJ, Langerak AW, Bruggemann M, Evans PA, Hummel M, Lavender FL, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia. 2003;17:2257\u2013317.","journal-title":"Leukemia"},{"key":"1132_CR20","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1111\/j.1348-0421.1991.tb01623.x","volume":"35","author":"Y Eizuru","year":"1991","unstructured":"Eizuru Y, Minematsu T, Minamishima Y, Ebihara K, Takahashi K, Tamura K, et al. Rapid diagnosis of cytomegalovirus infections by direct immunoperoxidase staining with human monoclonal antibody against an immediate-early antigen. Microbiol Immunol. 1991;35:1015\u201322.","journal-title":"Microbiol Immunol"},{"key":"1132_CR21","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1365-2141.1994.tb03263.x","volume":"86","author":"H Gondo","year":"1994","unstructured":"Gondo H, Minematsu T, Harada M, Akashi K, Hayashi S, Taniguchi S, et al. Cytomegalovirus (CMV) antigenaemia for rapid diagnosis and monitoring of CMV-associated disease after bone marrow transplantation. Br J Haematol. 1994;86:130\u20137.","journal-title":"Br J Haematol"},{"key":"1132_CR22","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1182\/blood.V87.6.2476.bloodjournal8762476","volume":"87","author":"F Cervantes","year":"1996","unstructured":"Cervantes F, Pierson BA, McGlave PB, Verfaillie CM, Miller JS. Autologous activated natural killer cells suppress primitive chronic myelogenous leukemia progenitors in long-term culture. Blood. 1996;87:2476\u201385.","journal-title":"Blood"},{"key":"1132_CR23","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1046\/j.1365-2141.1996.4991043.x","volume":"93","author":"LM Silla","year":"1996","unstructured":"Silla LM, Pincus SM, Locker JD, Glover J, Elder EM, Donnenberg AD, et al. Generation of activated natural killer (A-NK) cells in patients with chronic myelogenous leukaemia and their role in the in vitro disappearance of BCR\/ABL-positive targets. Br J Haematol. 1996;93:375\u201385.","journal-title":"Br J Haematol"},{"key":"1132_CR24","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1600-0609.2010.01501.x","volume":"85","author":"P Rohon","year":"2010","unstructured":"Rohon P, Porkka K, Mustjoki S. Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy. Eur J Haematol. 2010;85:387\u201398.","journal-title":"Eur J Haematol"},{"key":"1132_CR25","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1182\/blood.V90.7.2529","volume":"90","author":"JJ Molldrem","year":"1997","unstructured":"Molldrem JJ, Clave E, Jiang YZ, Mavroudis D, Raptis A, Hensel N, et al. Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. Blood. 1997;90:2529\u201334.","journal-title":"Blood"},{"key":"1132_CR26","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/79526","volume":"6","author":"JJ Molldrem","year":"2000","unstructured":"Molldrem JJ, Lee PP, Wang C, Felio K, Kantarjian HM, Champlin RE, et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med. 2000;6:1018\u201323.","journal-title":"Nat Med"},{"key":"1132_CR27","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1002\/1521-4141(200203)32:3<773::AID-IMMU773>3.0.CO;2-U","volume":"32","author":"B Lowin-Kropf","year":"2002","unstructured":"Lowin-Kropf B, Kunz B, Schneider P, Held W. A role for the src family kinase Fyn in NK cell activation and the formation of the repertoire of Ly49 receptors. Eur J Immunol. 2002;32:773\u201382.","journal-title":"Eur J Immunol"},{"key":"1132_CR28","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1084\/jem.190.8.1189","volume":"190","author":"P Gadue","year":"1999","unstructured":"Gadue P, Morton N, Stein PL. The Src family tyrosine kinase Fyn regulates natural killer T cell development. J Exp Med. 1999;190:1189\u201396.","journal-title":"J Exp Med"},{"key":"1132_CR29","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1006\/cimm.1995.1207","volume":"165","author":"C Pignata","year":"1995","unstructured":"Pignata C, Prasad KV, Hallek M, Druker B, Rudd CE, Robertson MJ, et al. Phosphorylation of src family lck tyrosine kinase following interleukin-12 activation of human natural killer cells. Cell Immunol. 1995;165:211\u20136.","journal-title":"Cell Immunol"},{"key":"1132_CR30","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1200\/JCO.2007.12.0329","volume":"25","author":"A Quintas-Cardama","year":"2007","unstructured":"Quintas-Cardama A, Kantarjian H, O\u2019Brien S, Borthakur G, Bruzzi J, Munden R, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol. 2007;25:3908\u201314.","journal-title":"J Clin Oncol"},{"key":"1132_CR31","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1365-2141.2008.07108.x","volume":"141","author":"H Lavallade de","year":"2008","unstructured":"de Lavallade H, Punnialingam S, Milojkovic D, Bua M, Khorashad JS, Gabriel IH, et al. Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis. Br J Haematol. 2008;141:745\u20137.","journal-title":"Br J Haematol"},{"key":"1132_CR32","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1200\/JCO.2005.01.032","volume":"23","author":"GC Jayson","year":"2005","unstructured":"Jayson GC, Parker GJ, Mullamitha S, Valle JW, Saunders M, Broughton L, et al. Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab\u2032, leads to fluid accumulation and is associated with increased tumor vascularized volume. J Clin Oncol. 2005;23:973\u201381.","journal-title":"J Clin Oncol"},{"key":"1132_CR33","doi-asserted-by":"crossref","unstructured":"Imagawa J, Tanaka H, Matsumoto K, Morita K, Harada Y, Harada H (2012) A sharp fluctuation in peripheral blood cells shortly after dasatinib administration. Int J Hematol (in press)","DOI":"10.1007\/s12185-012-1138-2"},{"key":"1132_CR34","doi-asserted-by":"crossref","unstructured":"Mustjoki S, Rousselot P, Jalkanen S, Kreutzman A, Melo T, Lahesmaa A-M, et al. Dasatinib induce a rapid, dose-controllable mobilization of cytotoxic lymphocytosis: A novel immunomodulatory effect associated with prolonged therapy responses in advanced leukemia. #1204, The 52th ASH Annual Meeting and Exposition. 2010.","DOI":"10.1182\/blood.V116.21.1204.1204"},{"key":"1132_CR35","doi-asserted-by":"crossref","unstructured":"Al-Ameri A, Kantarjian H, Borthakur G, Bahceci E, Szatrowski T, Damokosh A, et al. Opportunistic infection are uncommon with dasatinib in patients with chronic myeloid leukemia in chronic phase (CP-CML). #1120, The 51th ASH Annual Meeting and Exposition. 2009.","DOI":"10.1182\/blood.V114.22.1120.1120"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-012-1132-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-012-1132-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-012-1132-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T19:28:31Z","timestamp":1594409311000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-012-1132-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,6]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["1132"],"URL":"https:\/\/doi.org\/10.1007\/s12185-012-1132-8","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,6]]}}}